Innoplexus, a Germany and India-based DaaS (Data as a Service) startup, has announced the closing of their pre-Series A funding from HCS, a Germany-based Venture Capital Fund. With the capital raised, the startup plans to file more patent applications, further develop their trademark platform, iPlexus, and invest in marketing.
Innoplexus helps Life Sciences companies generate actionable insights across pre-clinical, clinical, regulatory and commercial stages of a drug. It’s Data-as-a-Service (DaaS) engine with real-time data and insights along with an ecosystem of Continuous Analytics as a Service (CAaaS) applications aim to help enterprises make better data-driven decisions.
Speaking on the recent development, Gunjan Bhardwaj, Co-Founder and CEO, Innoplexus said:
“We envision to fundamentally transform the Data-as-a-Service landscape for Life Sciences by leveraging machine learning and artificial intelligence to generate insights from the public as well as enterprise data.”
Gaurav Tripathi, Co-Founder and CEO, Innoplexus, India, further added:
“We are working in cutting edge technology areas of Information Retrieval, Network Analysis, Computer Vision and Ontologies and are one of the rare startups with a strong focus on creating proprietary Intellectual Property.”
The startup further revealed that Hans-Christian Semmler, Managing Shareholder of HCS, will join as Chairman of the supervisory board of Innoplexus. He started his career in investment banking eventually serving as the CFO of VosslohAG and then as the CEO of Haupt Pharma AG.